참고문헌 (16)

1. World Health Organization. Antimicrobial resistance [Internet]. Geneva: World Health Organization;？2021 [cited 2022 Oct 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.？ 

2. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. London:？Government of the United Kingdom, 2016.？ 

3. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a？systematic analysis. Lancet 2022;399:629-55. 

4. Horcajada JP, Montero M, Oliver A, Sorli L, Luque S, Gomez-Zorrilla S, et al. Epidemiology and treatment？of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev？2019;32:e00031-19.？ 

5. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant,？extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim？standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81. 

6. Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, et al. P. aeruginosa bloodstream？infections among hematological patients: an old or new question? Ann Hematol 2012;91:1299-304. 

7. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas？aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation.？Haematologica 2010;95:1612-5.？ 

   상세보기

8. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and？development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.？Lancet Infect Dis 2018;18:318-27.？ 

   상세보기

9. Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR gram-negative bacteria.？Front Med (Lausanne) 2019;6:74.？ 

   상세보기

10. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. IDSA guidance on the treatment？of antimicrobial-resistant gram-negative infections: version 1.1 [Internet]. Arlington: Infectious Diseases？Society of America; 2022 [cited 2022 Oct 25]. Available from: https://www.idsociety.org/practice-guideline/amr-guidance/.？ 

11. Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A.？baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based？on the mechanisms of resistance to carbapenems. Infection 2020;48:835-51.？ 

12. Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, et al. Analysis of the clinical pipeline of？treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob？Agents Chemother 2022;66:e0199121.？ 

13. Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). J Antimicrob？Chemother 2017;72:1386-95.？ 

14. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a？novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2014;74:31-51.？ 

15. Hakeam HA, Askar G, Al Sulaiman K, Mansour R, Al Qahtani MM, Abbara D, et al. Treatment of？multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: a multicenter retrospective study. J Infect Public Health 2022;15:1081-8.？ 

    상세보기

16. Merck Sharp & Dohme LLC. Product information. Zerbaxa (ceftolozane-tazobactam) [Internet]. Rahway:？Merck Sharp & Dohme LLC; 2022 [cited 2022 Sep 22]. Available from: https://www.merck.com/product/usa/pi_circulars/z/zerbaxa/zerbaxa_pi.pdf.？ 

저자의 다른 논문 :

조중범 (3)